Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus TPF neoadjuvant therapy for unresectable locally advanced head and neck squamous cell carcinoma
2006-005329-42Phase 2Completed
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Start
- Mar 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, docetaxel, cisplatin and fluorouracil in head and neck squamous cell carcinoma (HNSCC), sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello. Primary endpoint: Objective response rate. Started Mar 2007; status: completed.
02
Drugs
cetuximabdocetaxelcisplatinfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2006-005329-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005329-42.